Immune suppressant ineffective in treating leprosy inflammation

March 30, 2017

Throughout the course of a leprosy infection, patients often have episodes of painful inflammation affecting their skin and nerves. Researchers have continuously struggled with finding effective drugs to treat these so-called "type 1 reactions," and now one more study has come up empty-handed. The immune-suppressant azathioprine did not improve the standard of care treatment with steroids, researchers report in PLOS Neglected Tropical Diseases.

Leprosy, or Hansen's disease, is a long-term infection with the bacteria Mycobacterium leprae or Mycobacterium lepromatosis. 189,000 people worldwide have chronic leprosy infections, which can remain asymptomatic for years but eventually lead to immune reactions that cause long-term damage to the nerves, skin, and eyes. Treating type 1 reactions fast is key to preventing long-term damage. The drug azathioprine has been used as an immune-suppressant in other contexts included to treat rheumatoid arthritis and Crohn's disease.

In the new work, Diana Lockwood of the London School of Hygiene & Tropical Medicine, with colleagues at the Leprosy Mission Trust India, randomized 345 leprosy patients with type 1 reactions into four groups. Each received either a 20 week course of the steroid prednisone alone, or prednisone plus azathioprine for 24, 36, or 48 weeks. The patients were followed and the status of their skin and nerve symptoms recorded.

At the end of the study, 76 percent of patients in all groups had some improvement in their symptoms. However, 36 percent of patients required additional courses of steroids due to recurrence of their leprosy reactions, and the majority of patients with motor or sensory nerve damage--as opposed to skin symptoms--had no improvement. Moreover, azathioprine did not reduce the recurrence rate or improve outcomes for either skin or nerve symptoms compared to the prednisone only group.

"We have shown that it is difficult to improve on steroid treatment for leprosy inflammation," the researchers conclude. "The findings highlight the difficulty in switching off leprosy inflammation and the need for better treatments for reactions and nerve damage. There is also a research need to identify patients who have recurrences and optimize treatments for them," they add.
-end-
In your coverage please use this URL to provide access to the freely available article in PLOS Neglected Tropical Diseases: http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0005348

Citation: Lockwood DNJ, Darlong J, Govindharaj P, Kurian R, Sundarrao P, John AS (2017) AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings. PLoS Negl Trop Dis 11(3): e0005348. doi:10.1371/journal.pntd.0005348

Funding: This work was funded by The Moulton Trust. The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

PLOS

Related Steroids Articles from Brightsurf:

Study shows protective role sex steroids play in COVID-19
''Sex and Covid-19: A protective role for reproductive steroids,'' by Graziano Pinna, research associate professor in psychiatry, analyzes existing research to look at reasons why COVID-19 symptom severity and mortality are more frequent in men than in women and in older people.

New RA guideline emphasizes maximizing methotrexate and biologics, minimizing steroids
The American College of Rheumatology (ACR) will preview its 2020 Guideline for the Management of Rheumatoid Arthritis (RA) at ACR Convergence, the ACR's annual meeting.

Microwaves are useful to combine amino acids with hetero-steroids
Aza-steroids are important class of compounds because of their numerous biological activities.

Early steroids improve outcomes in patients with septic shock
Some critically ill patients with septic shock need medications called vasopressors to correct dangerously low blood pressure.

Cumulative doses of oral steroids linked to increased blood pressure
Cumulative doses of oral steroids in patients with chronic inflammatory diseases are associated with increased hypertension (blood pressure) for those who take them regularly, found new research in CMAJ (Canadian Medical Association Journal).

Fewer steroids, no plasma exchange: A change in treatment for vasculitis
The insights from the PEXIVAS Trial, a 10-year study, shows treatment for ANCA-associated vasculitis can use half the standard dosage of steroids and involve no blood plasma exchanges.

Steroids could do more harm than good in treating coronavirus
Steroids should be avoided in the treatment of the current novel coronavirus, experts have advised.

Are steroids used too much for patients with inflammatory bowel disease?
Steroid therapy is commonly used to treat acute attacks of the inflammatory bowel diseases ulcerative colitis and Crohn's disease; however, because it does not provide long-term benefits and it carries a risk of serious side effects, it should not be used to treat inflammatory bowel disease for more than three months.

One third of patients with severe asthma are taking harmful doses of oral steroids
A third of patients with severe asthma are taking harmful doses of oral steroids, according to a study of several thousand people in The Netherlands, presented at the European Respiratory Society International Congress.

Oral steroids put patients with inflammatory disease at high risk of infection
Oral steroid use in patients with the inflammatory diseases polymyalgia rheumatica and/or giant cell arteritis significantly increased the risk of infection, and the risk increased with higher doses, found a study in CMAJ (Canadian Medical Association Journal).

Read More: Steroids News and Steroids Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.